2h
NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...
Recovery from deadly influenza infection may hinge on helping the lungs heal in addition to stopping the virus, according to ...
Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice ...
MyChesCo on MSN
Traws Pharma Pushes Ahead on COVID and Flu Antivirals as Costs Fall and Pipeline Advances
Traws Pharma, Inc. (NASDAQ: TRAW) reported third quarter 2025 financial results and highlighted steady momentum across its ...
Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...
Two complementary studies led by researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), today ...
Merck will acquire Cidara for $9.2B, adding breakthrough flu antiviral CD388 to its pipeline as it expands beyond its ...
Ruvidar and Rutherrin show strong potential in treating bladder cancer, solid tumors, and HSV-1—including drug-resistant ...
WASHINGTON -- Assessing sustained virological response (SVR) to hepatitis C virus (HCV) therapy at 4 weeks after treatment ...
Merck & Co Inc <a href=" target="_blank">(MRK.N) has agreed to acquire drugmaker OncoImmune in a deal that will give it control of a drug that could help ease symptoms and reduce deaths in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback